# MB-105 in Patients With CD5 Positive T-cell Lymphoma

Source: https://onco.cc/trials/nct06534060/  
OnCo record `nct06534060` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Genetic: MB-105 in non-Hodgkin lymphoma, run by March Biosciences Inc, now recruiting.

## Summary

MB-105 in Patients With CD5 Positive T-cell Lymphoma is a phase 2 interventional study registered as NCT06534060 by March Biosciences Inc, with 46 participants planned, started 2025-02-15 and due to reach its primary completion in 2028-02. Interventions recorded: Genetic: MB-105.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06534060
- Phase: 2
- Setting: A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).
- Sponsor: March Biosciences Inc
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06534060: https://clinicaltrials.gov/study/NCT06534060

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06534060.json